Glofitamab
Cat. No.: IBDI-431851
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma.
Product Details
| Target |
CD20 |
| Appearance |
Liquid |
| Synonyms |
RO7082859 |
| SMILES |
[Glofitamab] |
| Purity |
95.00% |
Storage & Handling
| Shipping |
Shipping with dry ice. |
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
